Replies to post #2266 on Vitro Diagnostics Inc. (fka VODG)

[JonesBur]

Agree completely with the filing delinquency. If they hadn't stopped reporting a couple years ago, I wouldn't have starting selling shares here and there, and wouldn't have sold shares on this recent run-up. Without them, the financials are merely just hearsay and any bigger investor won't touch it.

Other than that, the latest release does sound very good and as I've already said, believe it will keep the pps in the .20s, which is great for this company. The volume has dropped off lately, but still multiple times higher than historically. However it's obvious that very few people actually know about this company, and rightfully so, but they seem to be on track for spreading the word.

[Potse]

VODG(.22)...next 4 months should be interesting......

The next 4 months for VODG could turn out to be pretty interesting. Assuming the company maintains its schedule for financial performance press releases, we should be seeing at least two PRs in that time frame (FY 2018 and Q1 2019).

Given how informative its PRs have become, each of those press releases could be catalysts for tradeable spikes in the share price or sustained moves into higher trading ranges.

FY 2018 revenue should be well over $500k, and the quarter-over-quarter comparisons in early 2019 should look favorable. VODG has come a long way from the days when a $5-10K quarter was considered good.

I think it is a good idea to go back and read that Q3 press release again (see post above). VODG is telegraphing that business operations (on a number of fronts) are about to ramp up significantly in this coming year. That information regarding IRB-activity in foreign countries is potentially huge, especially when you consider how VODG's revenue to date has been positively influenced by exposure to basically just two clinics (New Zealand, Cayman Island).

https://vitrobiopharma.com/vitro-biopharma-3rd-quarter-ended-july-31st-2018-financial-results-of-operations/